SCHEMBL7052910

SCHEMBL7052910

CCOC(=O)c1ccc(N2CCC[C@H](N)C2)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
PIM1 P11309 1/20 0.47
CLK2 P49760 1/20 0.47
MAP4K2 Q12851 1/20 0.47
CAMK2D Q13557 1/20 0.47
DYRK1A Q13627 1/20 0.47
PIM3 Q86V86 1/20 0.47
AURKB Q96GD4 1/20 0.47
PRKD2 Q9BZL6 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
STK17A Q9UEE5 1/20 0.47
MAP4K5 Q9Y4K4 1/20 0.47
DPP4 P27487 8/20 0.44
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7467833 0.89 PRKD3 (0.48) PRKD3MAP4K4PIM1CLK2MAP4K2
SCHEMBL7463266 0.87 PRKD3 (0.47) PRKD3MAP4K4PIM1CLK2MAP4K2
SCHEMBL7468709 0.86 PRKD3 (0.45) PRKD3MAP4K4PIM1CLK2MAP4K2
SCHEMBL4508521 0.84 MAPT (0.52) MAPTKDM4EMEN1USP2ALDH1A1
SCHEMBL7468160 0.81 DPP4 (0.56) PRKD3MAP4K4PIM1CLK2MAP4K2
SCHEMBL7051582 0.81 DPP4 (0.56) PRKD3MAP4K4PIM1CLK2MAP4K2
SCHEMBL7052909 0.80 RAB9A (0.43) MAPTKDM4EMEN1USP2ALDH1A1
SCHEMBL7050644 0.79 OPRK1 (0.49) MAPTKDM4EMEN1USP2ALDH1A1
SCHEMBL31542266 0.78 MAPT (0.46) DPP4MAPTKDM4EMEN1USP2
SCHEMBL24778719 0.76 MAPT (0.45) DPP4MAPTKDM4EMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030040531-A1 Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist MEIJI SEIKA KAISHA, LTD. (JP) 2003-02-27 US disclosed
EP-1250935-A1 REMEDIES FOR REPERFUSION INJURY CONTAINING INTEGRIN ALPHAvBETA3 ANTAGONIST MEIJI SEIKA KAISHA LTD. (JP) 2002-10-23 EP disclosed
EP-1227083-A1 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS MEIJI SEIKA KAISHA LTD. (JP) 2002-07-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040531-A1 Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist ITGB3, ITGAV, ITGB1 PRKD3 679/4885MAP4K4 3892/4885PIM1 4348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.